20 mg/ml
Trade Name
Imjudo
Concentrate for solution for infusion
Request Type
New Registration
Drug Type
Biological
Approval Date
SFDA Approved Use
Imjudo in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD-1/PD-L1 inhibitor.